Hospital
Upmc Washington
Upmc Washington was paid $11.22M by Medicaid between Jan 2018 and Nov 2024, across 295 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoUPMC WASHINGTON
WASHINGTON, PA 15301
WASHINGTON, PA 15301
33aNPI1609984889assigned 08/28/2006
33bProvider typeSpecial Hospital
28Total paid$11.22M
24GClaims400,739
24DCodes billed295
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Special Hospital providers in Pennsylvania
Rank by total paid#2 of 7
Median peer was paid$1.50M
This provider vs. median7.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,016 | $38K | |
| 2019 | 1,456 | $130K | |
| 2020 | 48,638 | $1.28M | |
| 2021 | 207,242 | $5.71M | |
| 2022 | 57,388 | $1.43M | |
| 2023 | 53,114 | $1.53M | |
| 2024incomplete | 31,885 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 19,663 | 19,069 | $1.96M |
| G0378 | Hospital observation service, per hour | 15% | 2,118 | 1,963 | $1.71M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 9.9% | 28,372 | 6,290 | $1.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 4,170 | 3,817 | $580K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 4,403 | 4,211 | $529K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 7,089 | 6,774 | $385K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 5,564 | 5,471 | $342K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.3% | 6,234 | 1,415 | $259K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 1,200 | 1,162 | $186K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 4,524 | 4,410 | $160K |
| 80050 | General health panel | 1.2% | 3,059 | 2,990 | $133K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 5,302 | 5,201 | $121K |
283 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 5,334 | $118K |
| 80053 | Comprehensive metabolic panel | 1.0% | 16,558 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,181 | $106K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,073 | $103K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,898 | $103K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,662 | $100K |
| 59025 | Fetal non-stress test | <1% | 1,589 | $98K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,231 | $83K |
| 87481 | <1% | 2,056 | $76K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,347 | $72K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,465 | $62K |
| 80061 | Lipid panel | <1% | 4,618 | $60K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,896 | $59K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 352 | $59K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 223 | $58K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 382 | $57K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,350 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,415 | $55K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,873 | $53K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 653 | $52K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 253 | $52K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,843 | $51K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 333 | $50K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,491 | $49K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,245 | $47K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,136 | $46K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,214 | $44K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,539 | $43K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 700 | $42K |
| 84484 | <1% | 5,935 | $42K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 536 | $41K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 540 | $40K |
| 77066 | Tomosynthesis, mammo | <1% | 504 | $40K |
| 72141 | <1% | 179 | $39K | |
| 76641 | <1% | 714 | $37K | |
| 88142 | <1% | 2,204 | $37K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,838 | $34K |
| 88342 | <1% | 956 | $33K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 178 | $33K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,034 | $32K |
| 82607 | <1% | 2,488 | $29K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 592 | $27K |
| 93976 | <1% | 370 | $26K | |
| 97161 | <1% | 776 | $26K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,016 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 584 | $26K |
| 71250 | <1% | 444 | $25K | |
| 86780 | <1% | 1,742 | $25K | |
| X0621 | <1% | 113 | $25K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 503 | $24K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,857 | $24K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,519 | $24K |
| 83735 | <1% | 6,261 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,569 | $24K |
| 87081 | <1% | 4,175 | $23K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 239 | $22K |
| 76801 | <1% | 499 | $22K | |
| 81514 | <1% | 129 | $21K | |
| 93971 | <1% | 376 | $21K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 438 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,834 | $20K |
| 83880 | <1% | 825 | $20K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 124 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 355 | $19K |
| 87428 | <1% | 622 | $18K | |
| C1769 | Guide wire | <1% | 145 | $18K |
| 87150 | <1% | 429 | $18K | |
| 81513 | <1% | 574 | $18K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 310 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 831 | $17K |
| 83690 | <1% | 5,858 | $16K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,146 | $15K |
| 84466 | <1% | 884 | $15K | |
| 85730 | <1% | 3,363 | $15K | |
| 93970 | <1% | 181 | $14K | |
| 84702 | <1% | 767 | $13K | |
| 81001 | <1% | 6,852 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,026 | $13K |
| 86900 | <1% | 1,096 | $12K | |
| 80074 | <1% | 217 | $12K | |
| 76536 | <1% | 278 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,628 | $12K |
| 85610 | <1% | 4,617 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 478 | $11K |
| 82746 | <1% | 958 | $11K | |
| 87040 | <1% | 629 | $11K | |
| 93017 | <1% | 379 | $10K | |
| 83970 | <1% | 273 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 148 | $10K |
| 97597 | <1% | 430 | $10K | |
| 86762 | <1% | 507 | $10K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 507 | $10K |
| 84145 | <1% | 667 | $9K | |
| 87186 | <1% | 1,148 | $9K | |
| 86803 | <1% | 527 | $9K | |
| 97165 | <1% | 392 | $9K | |
| 80076 | <1% | 1,088 | $8K | |
| 87340 | <1% | 617 | $8K | |
| 82043 | <1% | 1,069 | $8K | |
| 94729 | <1% | 290 | $8K | |
| 76775 | <1% | 233 | $8K | |
| 84439 | <1% | 921 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 334 | $7K |
| 83540 | <1% | 884 | $7K | |
| 81025 | <1% | 2,564 | $7K | |
| 86850 | <1% | 1,070 | $7K | |
| 73564 | <1% | 360 | $7K | |
| 72110 | <1% | 370 | $7K | |
| 81003 | <1% | 2,942 | $7K | |
| 94726 | <1% | 258 | $7K | |
| 86618 | <1% | 278 | $6K | |
| 84403 | <1% | 226 | $6K | |
| 84436 | <1% | 660 | $6K | |
| 84146 | <1% | 267 | $6K | |
| 73610 | <1% | 354 | $6K | |
| 82728 | <1% | 510 | $6K | |
| 82248 | <1% | 936 | $6K | |
| 73630 | <1% | 590 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 430 | $6K |
| 85379 | <1% | 625 | $6K | |
| 77065 | Tomosynthesis, mammo | <1% | 104 | $6K |
| 84479 | <1% | 595 | $6K | |
| 88360 | <1% | 328 | $6K | |
| 84480 | <1% | 644 | $5K | |
| 83605 | <1% | 835 | $5K | |
| 74183 | <1% | 14 | $5K | |
| 73221 | <1% | 25 | $5K | |
| 82550 | <1% | 856 | $5K | |
| 82553 | <1% | 619 | $5K | |
| 85027 | <1% | 779 | $5K | |
| 72100 | <1% | 254 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $5K |
| 73030 | <1% | 314 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 397 | $5K |
| 84703 | <1% | 516 | $4K | |
| 86038 | <1% | 293 | $4K | |
| 82565 | <1% | 823 | $4K | |
| 72050 | <1% | 179 | $4K | |
| 74018 | <1% | 388 | $4K | |
| 72072 | <1% | 221 | $4K | |
| 83001 | <1% | 214 | $4K | |
| 73502 | <1% | 247 | $4K | |
| 84481 | <1% | 161 | $4K | |
| 86901 | <1% | 1,088 | $4K | |
| 90715 | <1% | 121 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 67 | $3K |
| 80164 | <1% | 179 | $3K | |
| J3490 | Unclassified drugs | <1% | 924 | $3K |
| 73130 | <1% | 290 | $3K | |
| 82784 | <1% | 166 | $3K | |
| 88341 | <1% | 68 | $3K | |
| 82948 | <1% | 2,688 | $3K | |
| 85007 | <1% | 776 | $3K | |
| 77049 | <1% | 16 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 581 | $3K |
| 82570 | <1% | 396 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 313 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 112 | $3K |
| 84100 | <1% | 476 | $3K | |
| 84153 | <1% | 119 | $3K | |
| 84160 | <1% | 356 | $3K | |
| 84550 | <1% | 393 | $2K | |
| 86800 | <1% | 130 | $2K | |
| 85651 | <1% | 885 | $2K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 111 | $2K |
| 82803 | <1% | 132 | $2K | |
| 86140 | <1% | 826 | $2K | |
| 82947 | <1% | 574 | $2K | |
| 80320 | <1% | 168 | $2K | |
| 87070 | <1% | 391 | $2K | |
| 84520 | <1% | 424 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,455 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $2K |
| 86617 | <1% | 45 | $2K | |
| 84450 | <1% | 245 | $2K | |
| 87807 | <1% | 197 | $2K | |
| 86431 | <1% | 216 | $2K | |
| 74022 | <1% | 95 | $2K | |
| 72158 | <1% | 12 | $2K | |
| 96376 | <1% | 407 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 36 | $1K |
| 94060 | <1% | 163 | $1K | |
| 73110 | <1% | 136 | $1K | |
| 70486 | <1% | 26 | $1K | |
| 87430 | <1% | 212 | $1K | |
| 72040 | <1% | 83 | $1K | |
| 77002 | <1% | 44 | $1K | |
| 82330 | <1% | 175 | $1K | |
| 85014 | <1% | 466 | $1K | |
| 73562 | <1% | 57 | $928.01 | |
| 73590 | <1% | 75 | $919.38 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,654 | $906.67 |
| 80178 | <1% | 112 | $901.70 | |
| 94664 | <1% | 270 | $874.22 | |
| 88304 | <1% | 224 | $863.74 | |
| 83655 | <1% | 77 | $852.50 | |
| 85018 | <1% | 363 | $852.05 | |
| 84402 | <1% | 29 | $845.10 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $805.17 |
| 74021 | <1% | 63 | $799.66 | |
| 86376 | <1% | 100 | $797.92 | |
| 82533 | <1% | 59 | $749.08 | |
| 80069 | <1% | 81 | $733.30 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,591 | $690.47 |
| 82977 | <1% | 79 | $668.88 | |
| 82150 | <1% | 146 | $664.49 | |
| 77080 | <1% | 15 | $638.83 | |
| 84460 | <1% | 87 | $627.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 94 | $601.14 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $569.40 |
| 88307 | <1% | 77 | $554.37 | |
| 97602 | <1% | 14 | $551.22 | |
| 82077 | <1% | 138 | $539.14 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 68 | $534.09 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 18 | $533.53 |
| 73080 | <1% | 46 | $510.09 | |
| 83002 | <1% | 29 | $470.05 | |
| 73521 | <1% | 28 | $468.45 | |
| 80051 | <1% | 91 | $447.77 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 508 | $414.36 |
| 71101 | <1% | 28 | $410.06 | |
| 76870 | <1% | 12 | $401.60 | |
| 83516 | <1% | 167 | $392.31 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 16 | $376.95 |
| 84132 | <1% | 85 | $344.97 | |
| 88344 | <1% | 12 | $339.04 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 805 | $338.96 |
| 82670 | <1% | 14 | $294.57 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 27 | $290.54 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,131 | $276.77 |
| 82105 | <1% | 12 | $244.82 | |
| 82010 | <1% | 58 | $238.75 | |
| 94010 | <1% | 33 | $230.85 | |
| 76770 | <1% | 12 | $222.95 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 525 | $213.08 |
| 94799 | <1% | 31 | $212.82 | |
| 83615 | <1% | 32 | $207.30 | |
| 36600 | <1% | 34 | $204.85 | |
| 86200 | <1% | 14 | $201.89 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,470 | $192.83 |
| 73090 | <1% | 15 | $158.14 | |
| 73140 | <1% | 12 | $129.15 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 618 | $126.23 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 657 | $122.63 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 634 | $122.01 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,813 | $109.11 |
| 95819 | <1% | 13 | $104.63 | |
| 76000 | <1% | 76 | $103.50 | |
| 76937 | <1% | 43 | $93.85 | |
| 89060 | <1% | 12 | $92.64 | |
| 82140 | <1% | 32 | $84.90 | |
| 82310 | <1% | 30 | $79.99 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 34 | $71.53 |
| 94760 | <1% | 140 | $65.79 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 517 | $60.27 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 14 | $58.92 |
| 87077 | <1% | 12 | $58.76 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 248 | $57.48 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 28 | $56.35 |
| 99153 | Mod sedat endo service >5yrs | <1% | 26 | $55.38 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 75 | $49.60 |
| 84295 | <1% | 19 | $42.25 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,867 | $31.75 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 382 | $30.46 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 51 | $26.69 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,355 | $24.49 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,717 | $22.84 |
| 99152 | <1% | 14 | $22.28 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 226 | $18.01 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $16.18 |
| 94761 | <1% | 13 | $12.75 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 21 | $8.25 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 204 | $2.22 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 255 | $2.20 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 36 | $0.65 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 12 | $0.12 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 46 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 111 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 26 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 96 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 17 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 14 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEINER, JARED (CFO)
| Provider | Location | Paid |
|---|---|---|
| Upmc Presbyterian Shadyside | Pittsburgh, PA | $125.54M |
| Upmc Greene | Waynesburg, PA | $2.67M |
| Upmc Presbyterian Shadyside | Pittsburgh, PA | $131K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.